Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma

Lenvatinib is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), but the effect of dose modification on its efficacy is unclear. We analyzed the relationship between the relative dose intensity during the initial 4 weeks of therapy [4W-relative dose intensity (RDI)] and...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:PLoS One
Main Authors: Kirino, Sakura, Tsuchiya, Kaoru, Kurosaki, Masayuki, Kaneko, Shun, Inada, Kento, Yamashita, Koji, Osawa, Leona, Hayakawa, Yuka, Sekiguchi, Shuhei, Okada, Mao, Wang, Wan, Higuchi, Mayu, Takaura, Kenta, Maeyashiki, Chiaki, Tamaki, Nobuharu, Yasui, Yutaka, Nakanishi, Hiroyuki, Itakura, Jun, Takahashi, Yuka, Asahina, Yasuhiro, Izumi, Namiki
Formato: Artigo
Idioma:Inglês
Publicado: Public Library of Science 2020
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7170221/
https://ncbi.nlm.nih.gov/pubmed/32310967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0231828
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares